
Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
安斯泰来在研的非激素类疗法可降低绝经相关中至重度血管舒缩症状(VMS)的发生频率和严重程度 2021年9月22日,东京 -安斯泰来制药集团...
Read more about 安斯泰来在北美绝经学会2021年年会的口头报告中发表3期SKYLIGHT 2TM临床试验的12周结果
安斯泰来与辉瑞联合开发的XTANDI®(通用名恩扎卢胺)在3期ARCHES临床试验中可将男性转移性激素敏感性前列腺癌的死亡风险降低34%...
Read more about XTANDI®(通用名恩扎卢胺)在3期ARCHES临床试验中可将男性转移性激素敏感性前列腺癌的死亡风险降低34%
-基于验证性EV-301试验总生存期结果的常规批准...
Read more about 美国FDA授予PADCEV® (enfortumab vedotin-ejfv)常规批准及扩展适应症:用于治疗局部晚期或转移性尿路上皮癌患者
–八篇摘要,涵盖FLT3突变阳性的急性髓性白血病、患者治疗偏好以及在难治性血液肿瘤上的临床应用。...
Read more about 在欧洲血液学协会年会(EHA2021),八篇新研究成果反映了安斯泰来对急性髓性白血病的承诺
安斯泰来3月提交的新药申请是用于治疗经抗癌药物治疗后进展的局部晚期或转移性尿路上皮癌...
